



ophthalmology
futures forums 2025

RETINA PROGRAMME

PAVILLON D'ARMENONVILLE
PARIS, FRANCE

Weds. 03 Sept.

RETINA FORUM 2025

Welcome

Welcome to Ophthalmology Futures 2025.

We are delighted to welcome you to our Annual Ophthalmology Futures Retina Forum to be held, once again in Paris. Now in our 14th year of highlighting retina innovation, the 2025 Forum will showcase 33 companies developing back of the eye medical products to address unmet patient needs. As in prior years, this in-person event will bring together leading innovators, practitioners, corporate leaders and investors.

One of our fundamental goals is to make each Ophthalmology Futures meeting unique, evaluating the landscape of existing platforms as well as exploring novel developments. For 2025, we will emphasize innovation for diabetic retinopathy and novel as well as time tested approaches for Neovascular AMD. There continues to be much interest in Cell and Gene therapies for rare and common back of the eye disease, and much debate regarding the evolution of paradigms related to the treatment of Geographic Atrophy. Surgical robotics is a novel topic which is bound to generate interest. We will also explore the changing investment landscape for retinal innovation both in Europe as well as in other regions of the world.

We are confident that you will enjoy the formal program as well as the networking opportunities that come with an in-person event. Ophthalmology Futures Forums would like to thank our key advisors, particularly Professors Adnan Tufail and Ursula Schmidt-Erfurth who, for many years, have helped us shape the Forum program.

We would also like to thank our corporate presenters and distinguished faculty for joining us, as well as our generous sponsors who allow us to maintain modest registration fees for all attendees!

Thank you for attending Ophthalmology Futures Retina Forum 2025 in Paris.

Keith Barton & Kuldev Singh

on behalf of the Ophthalmology Futures Team



Vision Futures Limited, London, UK.
Registered in England No: 8125858.



2026 FORUMS

Save the dates

RETINA FORUM

VIENNA

Weds. 30 Sept.

EUROPEAN FORUM

LONDON

Thurs. 10 Sept.



Keep up to date with the latest announcements
on our social channels

Help us make a difference

Your support helps create a
future without sight loss.

We can't do it without you.

moorfieldseyecharity.org.uk/support-us

We are the leading charity in the UK funding research into eye conditions like glaucoma and macular degeneration, and innovations in patient care to help patients worldwide. moorfieldseyecharity.org.uk

moorfields.eyecharity@nhs.net



Moorfields Eye Charity, 162 City Road, London EC1V 2PD
Telephone: [020 7566 2565](tel:02075662565)

PROGRAMME COMMITTEE

>> Ike Ahmed

Division Head, Ophthalmology, Trilium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

>> Jorge Alio

Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Vissum Corporation, Spain.

>> Gerd Auffarth

Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

>> Francesco Bandello

Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

>> David Chang

Altos Eye Physicians & Clinical Professor, University of California, San Fran, USA.

>> Steve Charles

Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

>> Paul Chew

Professor of Ophthalmology, National University of Singapore, Singapore.

>> Jost Jonas

Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

>> Sir Peng Khaw

Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

>> Shigeru Kinoshita

Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

>> Richard Lindstrom

Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

>> Ursula Schmidt-Erfurth

Professor & Chair, Medical University of Vienna, Austria.

>> Ingeborg Stalmans

Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

>> Paulo Eduardo Stanga

Professor & Founder, The Retina Clinic London, UK.

>> José-Alain Sahel

Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments of Ophthalmology, Quinze- Vingt National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

>> Julian D. Stevens

Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

>> Adnan Tufail

Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

>> Tien Yin Wong

Founding Head & Chair Professor, Tsinghua University, Beijing, China.

>> ADVISORS

>> Laurent Attias

SVP, Head of Strategy, BD&L & Market Access, Alcon Inc., USA.

>> Eugene de Juan

Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California, USA.

>> Tom Dunlap

Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

>> Malvina Eydelman

CEO, Collaborative Community on Ophthalmic Innovation

>> Reza Haque

SVP & Global Head of OIC, Ophthalmic Innovation Center, Santen Pharmaceutical.

>> Paul Hallen

VP & Global Head, Retina, Alcon, Texas, USA.

>> Jim Mazzo

Executive Chairman, Neurotech.

>> Naveed Siddiqi

Novo Ventures.

>> ORGANISING COMMITTEE

>> Keith Barton

Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK, Professor of Ophthalmology, UCL, UK.


>> Kuldev Singh

Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

>> Michael Sena

Operational Director, Ophthalmology Futures Forums, UK.

PREMIUM SPONSORS



>> PLATINUM



Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With an over 75-year heritage, we are the largest eye care device company in the world, with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in 60 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.

>> SILVER



BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients' vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of

millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

To learn more about BVI and its mission to advance the future of vision, visit www.bvimedical.com

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. With over 200,000 employees across 150 countries, 650 operations facilities and 18,000 stores, in 2023 the Company generated consolidated revenue of Euro 25.4 billion. Its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. EssilorLuxottica is

home to the most advanced lens technologies including Varilux, Stellest and Transitions, the most iconic eyewear brands including Ray-Ban and Oakley, the most desired luxury licensed brands and world-class retailers including LensCrafters and Sunglass Hut. The Company's OneSight EssilorLuxottica Foundation has given access to sustainable vision care to more than 760 million people in underserved communities.



Thanks to the generosity of our all of our sponsors, there is no fee for company presentations and Virtual registration is complimentary for everyone.

>> GOLD



At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater

VALUE by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.



STAAR Surgical (NASDAQ: STAA) is a global leader in implantable phakic intraocular lenses (ICLs), designed to reduce or eliminate the need for glasses or contacts. For over 30 years, STAAR has focused on developing and marketing its proprietary Implantable Collamer® Lenses, made from a biocompatible material proven to deliver long-term vision correction without removing

corneal tissue. The EVO ICL™ product line offers visual freedom through a quick, minimally invasive procedure. STAAR has sold over 3 million ICLs in 75+ countries. Founded in 1982 and headquartered in Lake Forest, California, STAAR also operates R&D, manufacturing, and packaging facilities in California and Switzerland.

Learn more at EVOICL.com and staar.com.

The ZEISS logo is the word "ZEISS" in a white, bold, sans-serif font, centered within a dark blue rectangular box with a slight wave at the bottom.

ZEISS Medical Technology: With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, ZEISS Medical Technology supports healthcare professionals in setting new standards of care with proven medical technology

and broad application competence based on cutting-edge innovations. www.zeiss.com

SPEAKERS

Panellists & Chairs Presenting Companies

>> CHAIRS & PANEILLISTS

A

- **Laurent Attias**
SVP, Corporate Strategy,
BD&L & M&A, Alcon

B

- **Francesco Bandello**
Professor & Chairman,
University Vita-Salute
- **Keith Barton**
Co-chair, Ophthalmology Futures Team
- **Dominik Beck**
CBPO CBD & Product Officer,
Carl Zeiss Meditec Inc.
- **Francine Behar-Cohen**
Founder & CIO, Eyevensys

C

- **Usha Chakravarthy**
Professor of Ophthalmology & Vision
Science, Queens' University of Belfast
- **Wiley Chambers**
Ophthalmic Pharmaceutical
Consultant, Ocular Advisers
- **Dolly Chang**
CSO, Kodiak Sciences, Inc.
- **Andrew Chang**
CCO, BVI Medical
- **Gemmy Cheung**
Professor & Head, Retina Research
Group, Singapore National Eye Centre
- **Victor Chong**
CMO, Clearside Biomedical
- **Julie Clark**
SVP, Clinical Development,
4 D Molecular Therapeutics
- **Thomas Ciulla**
President & CEO, Ikarovec
- **Art Ciociola**
Global Head, Quality,
Ocular Therapeutix
- **Daniela Couto**
General Partner, Biogeneration
Ventures

D

- **Nathaniel Dahan**
Senior Associate, Syncona
- **Michael Devoy**
EVP, CMO, Bayer

E

- **Malvina Eydelman**
CEO, Collaborative Community
on Ophthalmic Innovation

F

- **Daniela Ferrara**
Assistant Professor of Ophthalmology,
Roche-Genentech
- **Dominik Fischer**
Professor of Ophthalmology,
University of Oxford
- **Laurent Fischer**
President & CEO, Adverum
Biotechnologies
- **Jeffrey Franco**
CEO, OcuDyne

G

- **Robyn Guymer**
Deputy Director, Head of Macular
Research, Centre for Eye Research,
Australia

H

- **Paul Hallen**
VP & Global Head Retina, Alcon
- **Rafiq Hasan**
CEO, Complement Therapeutics
- **Houman Hemmati**
Co-founder & CMO, Optigo
Biotherapeutics, Inc.
- **Nancy Holekamp**
Principal Global Medical Science
Director, Roche products
- **Dmitrij Hristodorov**
General Partner, Forbion

I

- **Alessandro Iannaccone**
Global Medical Lead, Astellas Pharma

J

- **Wesley Jackson**
President & CEO, Valitor
- **Lionel Jouet**
Director of New Product Strategy,
Bausch + Lomb
- **Eugene de Juan**
Professor, ForSight Labs

K

- **Arshad Khanani**
Director of Clinical Research,
Sierra Eye Associates
- **Peter Kaiser**
CDO, Ocular Therapeutix
- **Alicia Kemble**
Senior Venture Associate,
Retinal Degeneration Fund

M

- **Federico Marchetti**
Director of Marketing - Equipment,
BVI Medical
- **Samarendra Mohanty**
President, Nanoscope Therapeutics
- **Michael O'Rourke**
CEO, Re-Vana Therapeutics

O

- **Rabia Gurses Ozden**
Clinical Development Executive,
Adverum Biotechnologies

P

- **Ram Palanki**
EVP, Commercial Strategy &
Operations, REGENXBIO

R

- **Philip Rosenfeld**
Professor of Ophthalmology,
Bascom Palmer Eye Institute

S

- **Reza Safaei**
SVP, Head of Medical Affairs,
Nordic Nanovector



- **Dirk Sauer**
Chair, Pulesight Therapeutics
- **Patricio Schlottmann**
Research Director, Charles Centro Oftalmológico
- **Ursula Schmidt-Erfurth**
Professor & Chair, Medical University of Vienna
- **Susan Schneider**
MD, Ashvattha Therapeutics
- **Steven Schwartz**
Professor, University of California
- **Surendra Sharma**
SVP Medical Affairs, Outlook Therapeutics
- **Raid Sherif**
CEO, Oculis SA
- **David Silverman**
Group Clinical Director, Roche
- **Rishi Singh**
CMO, Cleveland Clinic Hospitals
- **Michael Singer**
Retina Specialist, UT Health San Antonio
- **Sobha Sivaprasad**
Professor of Ophthalmology, Moorfields Eye Hospital
- **Rich Small**
CEO, Neurotech Pharmaceuticals
- **Marc de Smet**
Founder & Head, MicroInvasive Ocular Surgery Clinic
- **Paulo Eduardo Stanga**
Professor & Founder, The Retina Clinic London

T

- **Anna Tan**
Senior Consultant, Singapore National Eye Centre
- **Gavin Tan**
Consultant Ophthalmologist, Singapore National Eye Centre
- **Adnan Tufail**
Professor of Ophthalmology, Moorfields Eye Hospital
- **Sally Tucker**
SVP, Clinical Development, Opus Genetics

W

- **Andrew Want**
Global Medic Lead, Astellas Pharma
- **Stephane Wolf**
Global Head of Pipeline Commercial

#

- **4 D Molecular Therapeutics**
Julie Clark, SVP, Clinical Development

A

- **AAVantgarde Bio**
Jayashree Sahnii, CMO
- **Adverum Biotechnologies**
Laurent Fischer, President & CEO
- **Ashvattha Therapeutics**
Susan Schneider, MD

B

- **Boehringer Ingelheim**
Stephane Wolf, Global Head of Pipeline Commercial - Eye Health

C

- **Complement Therapeutics**
Rafiq Hasan, CEO

D

- **deepeye Medical**
Manuel Opitz, CEO & Co-founder

I

- **Ikarovec**
Thomas Ciulla, President & CEO
- **Infinite Medical Ventures**
Tom Williamson, Co-founder
- **Irida Health**
David Crabb, CSO

K

- **Kiora Pharmaceuticals**
Eric Daniels, CDO
- **Kodiak Sciences**
Dolly Chang, CSO

M

- **Medetia Pharmaceuticals**
Jean-Philippe Annereau, CEO
- **Medevis Consulting**
Kristine Morrill, Founder & President

N

- **Nanoscope Therapeutics**
Samarendra Mohanty, President
- **Neurotech Pharmaceuticals**
Rich Small, CEO

O

- **Ocudyne**
Jeffrey Franco, CEO
- **Ocular Therapeutix**
Peter Kaiser, CDO
- **Oculis SA**
Riad Sherif, CEO
- **Optigo Biotherapeutics**
Houman Hemmati, Co-founder & CMO
- **Opus Genetics**
Sally Tucker, SVP, Clinical Development
- **Outlook Therapeutics**
Surendra Sharma, SVP Medical Affairs

P

- **PulseMedica**
Nir Katchinsky, CEO
- **PulseSight Therapeutics**
Judith Greciet, CEO
- **Pykus Therapeutics**
Friedrich Asmus, CDO

R

- **Re-Vana Therapeutics**
Michael O'Rourke, CEO
- **REGENXBIO**
Ram Palanki, EVP Commercial Strategy & Operations
- **Roca Therapeutics**
Maeva Dufies, CSO

S

- **Samsara Vision**
Thomas Ruggia, CEO
- **SJJ Solutions**
Jasper Schootstra, CEO

U

- **Unedle**
Jeroen Wissink, CEO

V

- **Valitor**
Wesley Jackson, President & CEO

RETINA FORUM

Timings are in central European summer time

09:00 - 09:50

Registration

09:50 - 10:00

Welcome

- Keith Barton
- Kuldev Singh

10:00 - 10:30

Panel 1

Is Diabetic Retinopathy the Overlooked Elephant in the Room?

Panel

- Dolly Chang
- Art Ciociola
- Malvina Eydelman
- Ram Palanki
- Patricio Schlottmann
- Riad Sherif
- Anna Tan

Co-chairs

- Francesco Bandello
- Adnan Tufail

10:30 - 11:00

Panel 2

Robotics & Other Surgical Advances for Back of the Eye Diseases

Panel

- Dominik Beck
- Lionel Jouet
- Federico Marchetti
- Steven Schwartz
- Gavin Tan
- Paul Hallen

Co-chairs

- Marc de Smet
- Paulo Eduardo Stanga

11:00 - 11:20

Break

Networking Break

Sponsored by:

Alcon
SEE BRILLIANTLY

11:20 - 11:50

Panel 3

Neovascular AMD: Are the Novel Extended Interval Therapies Truly Making a Difference?

Panel

- Gemmy Cheung
- Michael Devoy
- Houman Hemmati
- Nancy Holekamp
- Michael O'Rourke
- Rabia Gurses Ozden
- Surendra Sharma

Co-chairs

- Usha Chakravarthy
- Robyn Guymer

11:50 - 12:20

Panel 4

The Future of Tyrosine Kinase Inhibitors & Other Adjunctive Agents for AMD: Exits or Bust?

Panel

- Jeffrey Franco
- Peter Kaiser
- Susan Schneider
- Michael Singer
- David Silverman
- Wesley Jackson

Co-chairs

- Francine Behar-Cohen
- Sobha Sivaprasad

12:20 - 13:00

Panel 5

Gene & Cell Therapies for Rare & Common Retinal Diseases: Hype Vs Progress

Panel

- Julie Clark
- Thomas Ciulla
- Laurent Fischer
- Alessandro Iannaccone
- Samarendra Mohanty
- Rich Small
- Sally Tucker

Co-chairs

- Dominik Fischer
- Arshad Khanani

InFocus Clinical was born out of the visible disconnect between large, traditional CROs and their clients. We have worked with both large and small biotechnology companies, pharmaceutical companies, and CROs. InFocus Clinical was founded with the centennial mission

of coalescing the best and brightest clinical research professionals and proven leaders in retina vitreous development to advance ophthalmology therapeutic development.
Find out more at www.infocusclinical.com

13:00 - 13:50

Break

Networking Lunch

Sponsored by:



13:50 - 15:20

Presentations

Company Presentations 1

- Re-Vana Therapeutics – Michael O'Rourke
- Oculis SA – Riad Sherif
- Optigo Biotherapeutics – Houman Hemmati
- Valitor – Wesley Jackson
- Ocular Therapeutix – Peter Kaiser
- Kodiak Sciences – Dolly Chang
- Boehringer Ingelheim – Stephane Wolf
- Ashvattha Therapeutics – Susan Schneider
- deepeye Medical – Manuel Opitz
- Infinite Medical Ventures – Tom Williamson
- Irida Health – David Crabb
- Oculdyne – Jeffrey Franco

15:20 - 15:30

Investment Perspective

15:30 - 16:00

Panel 6

The Retina Investment Landscape: Optimism or Fatigue?

Panel

- Andrew Chang
- Nathaniel Dahan
- Eugene de Juan
- Dmitriy Hristodorov
- Alicia Kemble

Chair

- Daniela Couto

16:00 - 16:40

Presentations

Company Presentations 2

- Samsara Vision – Thomas Ruggia
- Pykus Therapeutics – Friedrich Asmus
- PulseMedica – Nir Katchinskiy
- SJJ Solutions – Jasper Schootstra
- Uneedle – Jeroen Wissink

16:40 - 17:00

Break

Networking Break

17:00 - 19:00

Presentations

Company Presentations 3

- Medevis Consulting – Kristine Morrill
- Roca Therapeutics – Maeva Dufies
- Outlook Therapeutics – Surendra Sharma
- Kiora Pharmaceuticals – Eric Daniels
- Medetia Pharmaceuticals – Jean-Philippe Annereau
- AAVantgarde Bio – Jayashree Sahni
- Opus Genetics – Sally Tucker
- REGENXBIO – Ram Palanki
- Adverum Biotechnologies – Laurent Fischer
- Nanoscope Therapeutics – Samarendra Mohanty
- 4 D Molecular Therapeutics – Julie Clark
- Neurotech Pharmaceuticals – Rich Small
- Complement Therapeutics – Rafiq Hasan
- Ikarovec – Thomas Ciulla
- PulseSight Therapeutics – Judith Greciet

19:00 - 19:30

Panel 7

Geographic Atrophy & Intermediate AMD: Lessons Learned from Glaucoma & Other Chronic Disease

Panel

- Victor Chong
- Daniela Ferrara
- Rafiq Hasan
- Wiley Chambers
- Rishi Singh
- Dirk Sauer
- Reza Safaei
- Andrew Want

Co-chairs

- Philip Rosenfeld
- Ursula Schmidt-Erfurth

19:30 - 19:35

Summary

19:35 - 19:40

Concluding Comments from the Co-chairs

- Kuldev Singh
- Keith Barton

19:40 - 21:00

Reception

SPONSORS >> BRONZE



abbvie

Allergan is now AbbVie –
Your Vision. Our Mission.

At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of more than 75 years in eye care, we are focused on preserving and protecting vision for patients around the world.

We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease, and retinal diseases.

Learn more at AbbVieEyeCare.com

AURION
BIOTECH

Aurion Biotech's mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech. Its first drug candidate is for the treatment of corneal endothelial disease and has received regulatory and reimbursement approval in Japan. The Company has completed enrollment and dosing of its

clinical trial in the U.S. and Canada and has received Breakthrough Therapy Designation and Regenerative Medicines Advanced Therapy Designation from FDA to facilitate development of its drug candidate. Aurion Biotech is backed by Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.

Apellis

At Apellis, we combine courageous science and compassion to develop life-changing medicines for some of the most challenging diseases patients face. Our goal is to transform treatment for a broad range of debilitating diseases by controlling a part of the immune system known as the complement cascade.

We ushered in the first new class of complement medicine in 15 years, and now have two approved medicines targeting C3, the central

protein in the cascade. These include the first-ever FDA approved therapy for geographic atrophy, a leading cause of blindness around the world.

With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across rare, retinal, and neurological diseases and are further exploring what is possible by targeting C3.

BAUSCH + LOMB


medevis[™]
EVIDENCE & ACCESS MEDICAL COMMUNICATIONS

A team that embodies ophthalmology in Europe, we are Medevis Consulting. It starts with a Board of Directors led by Kristine Morrill and Paul Bikard and extends through to the management team and service leaders. Medevis Consulting represents a new approach that marries


Bausch + Lomb is a leading global eye care company celebrating over 170 years of expertise in ophthalmology. Our Surgical Division provides a comprehensive portfolio for anterior, posterior, premium and glaucoma surgery. The SeeLuma™ Fully Digital Surgical Visualization Platform is amongst our latest innovations, along with our next generation ELIOS™ technology for glaucoma surgery. The combined Stellaris Elite™ vision enhancement

system, the TENEOTM 317 M2 Excimer Laser, and the latest additions to our premium IOL portfolio, the LuxLife® and enVista Aspire™ IOLs, plus a complete retina portfolio, also feature in our range.

Meet the team on our booth during EURETINA and ESCRS congresses and learn more at our Bausch + Lomb Satellite Lunchtime Symposium on 13th September at 1pm in Auditorium 10.

passion, experience and diligence to every project.

Our Vision: To be the partner of choice for medical device innovators in ophthalmology.



Neurotech Pharmaceuticals, Inc. is a private clinical stage biotech company focused on developing transformative therapies to slow the progression of Macular Telangiectasia (MacTel) and other chronic retinal diseases through

its core platform technology, Encapsulated Cell Therapy (ECT).

To learn more, visit www.neurotechpharmaceuticals.com.



We focus on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Our expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Today, Nordic Pharma has a range of highly

specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Ophthalmology, Women's Health and Critical Care (Anaesthesia, Haematology, Oncology).

Our driving force is about innovative and efficient products to fight diseases. We strive to bring solutions to specific unmet medical needs, contributing to improved patient care.



Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis' highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01 eye drops, a topical candidate in Phase 3 for diabetic macular edema; OCS-02, a topical anti-TNF α eye drop candidate

for dry eye disease; and OCS-05, a neuroprotective candidate for acute optic neuritis. Headquartered in Switzerland with operations in the US and Iceland, Oculis' goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team and supported by leading healthcare investors.



Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across development, treatment, and outcomes. OTX-TKI (also known as AXPAXLI™), Ocular's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™

proprietary bioresorbable hydrogel-based technology. OTX-TKI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).



REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV

Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.



Théa is the leading independent European pharmaceutical company specialized in the research, development, and commercialization of eye care products. Based in Clermont-Ferrand, France, this family-owned and run company comprises more than 2000 collaborators and has

expanded by opening more than 35 affiliates and offices in Europe, North Africa, North and South America, and the Middle East. Its products are available in 75 countries. In 2023, Théa's turnover reached \$1 billion.

SPONSORS >>NEW INNOVATOR



4DMT is a clinical-stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases. We use our transformative vector discovery platform, termed Therapeutic Vector Evolution, to create customized and proprietary gene delivery vehicles (i.e., vectors) to deliver therapeutic payloads to specific tissue types associated with the

underlying disease via the optimal route of administration. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies.



Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care in ophthalmology with the aspiration of developing functional cures to restore vision and prevent blindness. Adverum leverages its proprietary intravitreal platform, to

develop a novel gene therapy candidate, Ixo-vec, as a one-time, in-office, injection for patients with nAMD. Adverum aspires to transform the standard of care, Preserve Sight For Life®, and create a profound societal impact around the globe.



CILIATECH is developing a groundbreaking concept called CID (Cilio-scleral Interpositioning Device): a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects. INTERCIL® Uveal Spacer is the first implant in the industry to reduce

IOP without penetrating the anterior chamber or creating subconjunctival filtration, for open and narrow angle patients. Clinical trials show IOP is reduced by 33% at 36 months (68% patients drop free, no reoperation needed) and without ECL risk.



EyeYon Medical Ltd. is a pioneer in ophthalmologic medical devices, focusing on developing cornea-focused sight-saving solutions for more than a decade. We believe in challenging technology barriers to save the vision of millions of eyes worldwide.

EyeYon Medical is driven by a multi-disciplinary team of visionaries along with investors who see a future world with a new standard of corneal treatments, saving the sight of all those suffering from serious cornea-related conditions.



Gore Ventures accelerates innovation by investing in promising new technologies and exploring market opportunities that are new to Gore.

Purposeful Innovation: Driven by our curiosity, creativity, and collaboration, Gore develops advanced materials and new technologies that improve lives and

industries. Inspired by our founders' inventive and entrepreneurial spirit, we're constantly growing our capabilities to address society's most complex technology challenges.



Kiora Pharmaceuticals (NASDAQ:KPRX) is a clinical-stage biotechnology company developing and commercializing products for the treatment of retinal diseases. KIO-301 is being developed to treat retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with retinal degeneration.

KIO-104 is being developed to treat retinal inflammatory diseases. It is a non-steroidal, immunomodulatory small-molecule inhibitor of dihydroorotate dehydrogenase. For more information, please visit www.kiorapharma.com, and follow us on our social media accounts including Twitter and LinkedIn.



Optigo Biotherapeutics is an innovative pre-clinical stage biotherapeutics company working to develop cutting-edge treatments to address vision loss from chronic ophthalmic diseases, many of which are currently treated by monthly or bimonthly injections of drugs into the eye(s) by a retina specialist.

We believe that by reducing the frequency at which each dose of drug is delivered, we will reduce the inconvenience, discomfort, risk and expense of existing treatments. In doing so, we hope to reduce the number of patients dropping out of their treatment cycles or having to skip doses due to inconvenient timing.



We are developing and delivering photo-crosslinked, biodegradable ocular drug delivery systems engineered to provide 6 months + sustained release for a broad range of therapeutic modalities, including Biologics, Peptides, Large and Small Molecules. Through innovative sustained-release

therapeutics, we aim to resolve the treatment burden of frequent intravitreal injections and improve the quality of care for patients with sight-threatening diseases. Re-Vana is working with several global pharmaceutical companies in conducting preformulation and preclinical feasibility studies.



ViaLase, Inc. is a globally-minded, venture and strategic capital-backed, clinical stage medical technology company located in Aliso Viejo, CA. ViaLase is focused on disrupting the conventional glaucoma treatment

paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care. For more information, visit www.ViaLase.com.

IS YOUR COMPANY INTERESTED IN SPONSORING A FORUM?

Showcase your organisation across both Retina & European Forums, contact: info@ophthalmology-futures.com



EssilorLuxottica is proud to be a Silver sponsor at Ophthalmology Futures Forums 2025.



Join us at Panel 2:
Myopia - Endpoints & Efficacy



Thursday, 11 September
10:35 - 11:10 CET

Visit us at our booth in the Gallery Room to learn more Essilor® Stellest® lenses



OFFICIAL SILVER SPONSOR OF OUR 2025 FORUMS

ZEISS at EURETINA 2025

Make data work
for you.

4 - 7 September 2025, Palais des congrès, Paris

ZEISS

Seeing beyond



**Visit us at EURETINA 2025
at booth #2.B20.**

Advancing retinal care with
ZEISS Retina Workflow!

zeiss.com/euretina

en-INT_31_030_01971 ©Carl Zeiss Meditec, Inc., 2025. All rights reserved.

The Future is EVO ICL™

Expand your offering. Elevate your outcomes.

The EVO ICL lens is an Rx only surgical implant that corrects distance vision for persons 21–45. Surgeons must be certified prior to use including training on contraindications, surgical procedure and potential benefits, risks, and complications of both the surgery and the lens. Please review the DFU available at <https://edfu.staar.com/edfu/> for complete safety and other information before performing the clinical procedure.

staar.com

 **STAAR™
SURGICAL**

Alcon

Together, We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Thanks to you, each year our products touch the lives of millions of people living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated portfolio of contact lenses, lens care solutions, and pharmaceutical and over-the-counter eye drops. Alcon is also at the forefront of innovation, partnering with Eye Care Professionals like you to bring the gift of sight to more people around the world.

That's been our legacy for more than 75 years—and continues to guide our focus towards the brilliant future ahead.

Learn more at alcon.com

CONNECT WITH US!



@AlconEyeCare
@AlconCareers



@Alcon
@MyAlcon



@AlconLife
@AlconCareers



@SeeAlconScience



@AlconLife

